×
About 65,900 results

ALLMedicine™ Pancreatic Cancer Center

Research & Reviews  31,179 results

Combinations of Phytochemicals More Efficiently than Single Components Activate Nrf2 an...
https://doi.org/10.1080/01635581.2021.1933097
Nutrition and Cancer; Cykowiak M, Krajka-Kuźniak V et. al.

Jun 14th, 2021 - Cancer prevention particularly related to aging can be improved by the use of phytochemicals combinations. In this study, we evaluated the effect of phenethyl isothiocyanate (PEITC), xanthohumol (XAN), indole-3-carbinol (I3C), and resveratrol (RES...

Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectabl...
https://doi.org/10.2217/pgs-2020-0183
Pharmacogenomics Li S, Zhang G et. al.

Jun 14th, 2021 - Aim: The prognosis of resectable pancreatic cancer patients with the same stage of disease is highly variable. The purpose of this study is to establish a scoring system for preoperative screening of resectable patients. Materials & methods: The c...

Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of...
https://doi.org/10.1016/j.canlet.2021.06.003
Cancer Letters; Nesbitt H, Logan K et. al.

Jun 13th, 2021 - The emergence of immune checkpoint inhibitors (ICI's) in the past decade has proven transformative in the area of immuno-oncology. The PD-1/PD-L1 axis has been particularly well studied and monoclonal antibodies developed to block either the recep...

The biological underpinnings of therapeutic resistance in pancreatic cancer.
https://doi.org/10.1101/gad.348523.121
Genes & Development; Beatty GL, Werba G et. al.

Jun 12th, 2021 - Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively a...

see more →

Guidelines  89 results

Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077959
Pancreas Okusaka T, Nakamura M et. al.

Mar 6th, 2020 - Clinical Practice Guidelines for Pancreatic Cancer were first published in 2006 by the Japan Pancreas Society, and they were revised in 2009, 2013, and 2016. In July 2019, the Clinical Practice Guidelines for Pancreatic Cancer 2019 were newly revi...

Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practic...
https://doi.org/10.1016/j.prro.2019.06.016
Practical Radiation Oncology; Palta M, Godfrey D et. al.

Sep 2nd, 2019 - This guideline systematically reviews the evidence for treatment of pancreatic cancer with radiation in the adjuvant, neoadjuvant, definitive, and palliative settings and provides recommendations on indications and technical considerations. The Am...

Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recomm...
https://doi.org/10.1001/jama.2019.10232
JAMA , Owens DK et. al.

Aug 6th, 2019 - Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its ...

Screening for Pancreatic Cancer Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
https://jamanetwork.com/journals/jama/fullarticle/2740726
JAMA

Aug 5th, 2019 - Importance Pancreatic adenocarcinoma is the third most common cause of cancer death among men and women in the United States. Objective To systematically review benefits and harms of screening for pancreatic adenocarcinoma to inform the US Prev...

see more →

Drugs  95 results see all →

Clinicaltrials.gov  33,105 results

Combinations of Phytochemicals More Efficiently than Single Components Activate Nrf2 an...
https://doi.org/10.1080/01635581.2021.1933097
Nutrition and Cancer; Cykowiak M, Krajka-Kuźniak V et. al.

Jun 14th, 2021 - Cancer prevention particularly related to aging can be improved by the use of phytochemicals combinations. In this study, we evaluated the effect of phenethyl isothiocyanate (PEITC), xanthohumol (XAN), indole-3-carbinol (I3C), and resveratrol (RES...

Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectabl...
https://doi.org/10.2217/pgs-2020-0183
Pharmacogenomics Li S, Zhang G et. al.

Jun 14th, 2021 - Aim: The prognosis of resectable pancreatic cancer patients with the same stage of disease is highly variable. The purpose of this study is to establish a scoring system for preoperative screening of resectable patients. Materials & methods: The c...

Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of...
https://doi.org/10.1016/j.canlet.2021.06.003
Cancer Letters; Nesbitt H, Logan K et. al.

Jun 13th, 2021 - The emergence of immune checkpoint inhibitors (ICI's) in the past decade has proven transformative in the area of immuno-oncology. The PD-1/PD-L1 axis has been particularly well studied and monoclonal antibodies developed to block either the recep...

The biological underpinnings of therapeutic resistance in pancreatic cancer.
https://doi.org/10.1101/gad.348523.121
Genes & Development; Beatty GL, Werba G et. al.

Jun 12th, 2021 - Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively a...

see more →

News  1,339 results

Racial and Ethnic Minorities Underrepresented in Pancreatic Cancer Clinical Trials
https://www.medscape.com/viewarticle/951997

May 26th, 2021 - Pancreatic cancer clinical trials conducted in the United States over the past few decades have not adequately reported or included racial and ethnic minority populations, results of a recent study suggest. Adequate inclusion of underrepresented m...

PARP Inhibitor Rucaparib Helps Shrink Pancreatic Tumors With Mutations
https://www.medscape.com/viewarticle/950901

May 11th, 2021 - NEW YORK (Reuters Health) - Most patients with pancreatic cancer and BRCA1/2 or PALB2 mutations had tumor shrinkage or no tumor growth after switching from chemotherapy to the oral PARP inhibitor rucaparib as maintenance therapy in a phase-2 study...

Pancreatic Cancer Surveillance in People at High Risk Not Tied to Better Outcomes
https://www.medscape.com/viewarticle/949359

Apr 15th, 2021 - NEW YORK (Reuters Health) - Surveillance of people at high hereditary risk for pancreatic ductal adenocarcinoma (PDAC) can lead to diagnosis at an earlier stage, but as yet there is no clear survival benefit, according to researchers in the Nether...

Ablative Radiation Extends Life in Unresectable Pancreatic Cancer
https://www.medscape.com/viewarticle/947758

Mar 18th, 2021 - For patients with inoperable pancreatic cancer, higher dose ablative radiation after chemotherapy induction may extend life, say investigators from Memorial Sloan Kettering Cancer Center in New York City. When delivering the radiation, adjustments...

Pegilodecakin No Aid to FOLFOX in Metastatic Pancreatic Cancer
https://www.medscape.com/viewarticle/946610

Mar 1st, 2021 - NEW YORK (Reuters Health) - Adding immunotherapy pegylated IL-10 (pegilodecakin) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) in patients with advanced gemcitabine-refractory pancreatic cancer does not improve overall survival, according...

see more →

Patient Education  93 results see all →